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a b s t r a c t
In clinical trials recombinant-modiﬁed vaccinia virus Ankara expressing the Mycobacterium tubercu-
losis antigen 85A (MVA85A) induces approximately 10 times more effector T cells than any other
recombinant MVA vaccine. We have found that in BCG primed subjects MVA85A vaccination reduces
transforming growth factor beta 1 (TGF-1) mRNA in peripheral blood lymphocytes and reduces
TGF-1 protein in the serum, but increases IFN- ELISPOT responses to the recall antigen SK/SD.
TGF-1 is essential for the generation of regulatory T cells and we see a correlation across vacci-
nees between CD4+CD25hiFoxP3+ cells and TGF-1 serum levels. This apparent ability to counteract
regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic
vaccines.
© 2008 Elsevier Ltd.
1. Introduction
Currently, the only tuberculosis (TB) vaccine available is BCG,
which although largely ineffective at protecting against adult pul-
monary disease does confer some protection against severe TB in
childhood and against leprosy [1]. Therefore, strategies for improv-
ing BCG efﬁcacy are required. Boosting BCGprimed T cell responses
witha secondvaccineencodinganantigenpresentwithinBCG(het-
erologous prime–boost) is a potential strategy for improving BCG
efﬁcacy.Modiﬁedvaccinia virusAnkara (MVA) is commonlyusedas
a vector to deliver the antigen in heterologous prime–boost strate-
gies and has been useful in boosting T cell responses to intracellular
pathogens such as HIV, malaria and hepatitis C [2–8]. Antigen 85A
is considered a leading candidate antigen for inclusion in a booster
vaccine for BCG. It is immunodominant in animal and human stud-
ies, is highly conserved amongst all mycobacterial species and is
present in all strains of BCG. Using a recombinant MVA express-
ing antigen 85A (MVA85A) to boost previous BCG vaccination in
BALB/c mice induces higher levels of antigen-speciﬁc IFN- secret-
ing T cells and higher levels of protection from Mycobacterium
tuberculosis (M. tb) challenge than BCG alone [9,10]. We have been
investigating the safety and immunogenicity of MVA85A in BCG
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naïve and BCG primed subjects in the UK [11,12]. In these stud-
ies, MVA85A has been found to induce levels of IFN- secreting
effector T cells approximately 10 times greater than those obtained
with any other MVA vaccine construct. The effects of MVA85A
vaccination on T cell regulatory mechanisms that typically limit
effector T cell responses have not been previously investigated.
FoxP3 is a master gene governing the development and function
of regulatory T cells. Expression of FoxP3 in transgenic mice and
ectopic expression of FoxP3 in human cells has been shown to
genetically reprogramTcells to a regulatoryphenotype [13,14].Nat-
urally occurring regulatory T cells are generated in the thymus are
CD4+CD25highandconstitute1–5%of circulatingCD4+cells. Trans-
forming growth factor beta 1 (TGF-1) is ubiquitously present in a
wide variety of cells and has opposing effects on the differentia-
tion and proliferation of multiple immune-cell types [15,16]. T cells
carry the TGF-1RI and TGF-1RII receptors and can be directly
inﬂuenced through binding of active TGF-1. TGF-1 is also a key
regulatorof the signalingpathways that initiate andmaintainFoxP3
expression and is essential for the generation and suppressive func-
tion of peripheral regulatory T cells [13,17,18]. Previously we have
found that TGF-1 is associated with the generation of regulatory
T cells and higher rates of parasitic growth in subjects infected
with Plasmodium falciparum [19]. The aim of this current study was
to determine the effect of vaccination with MVA85A, both in BCG
naïve and BCG primed subjects, on the immunoregulatory cytokine
TGF-1 and on the generation of regulatory CD4+CD25hiFoxP3+ T
cells.
0264-410X © 2008 Elsevier Ltd.
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2. Materials and methods
2.1. Clinical trials
Subjects were recruited for immunisation studies under pro-
tocols approved by the Medicines and Healthcare products
Regulatory Agency and Oxfordshire Research Ethics Commit-
tee and enrolled only after obtaining written informed consent.
www.clinicaltrials.gov identiﬁers: NCT00480688, NCT00423566,
NCT00480714 and NCT00427830. They were aged 18–55 and were
all seronegative for HIV, HBV and HCV at screening. Routine lab-
oratory haematology and biochemistry were performed prior to
vaccination and all values were within normal limits. Subjects vac-
cinated with either BCG alone or MVA85A alone had no history of
previous BCG vaccination, no evidence of BCG scar, were ELISPOT
negative for the M. tb-speciﬁc antigens ESAT-6 and CFP-10 and had
PPD responses on ELISPOT ranging from 0 to 68 (median 22) SFC
per 106 PBMC. Subjects vaccinated with BCG followed by MVA85A
had received BCG vaccination 10–20 years prior to screening, had a
visible BCG scar, were ELISPOT negative for the M. tb-speciﬁc anti-
gens ESAT-6 and CFP-10 and had PPD ELISPOT responses ranging
from 0 to 465 (median 177) SFC per 106 PBMC. All subjects were
followed-up for 6months,with blood samples taken at regular time
points. Two subjects had previously been vaccinated with vaccinia,
although none had received a vaccination with MVA. Pre-existing
immunity to vaccinia did not appear to effect the immune response
to MVA85A.
2.2. IFN- ELISPOT assay
The main immunological measure used to determine vaccine
immunogenicitywas the ex vivo IFN-ELISPOT. Thiswasperformed
on freshly isolated PBMC taken at the following time points: at the
day of vaccination (0), and then at 1, 2, 4, 8, 12, 16, 24 and 52 weeks
after vaccination aspreviously described [11]. Thesemeasurements
were carried out on fresh PBMCs using 7 pools of 9–10 15-mer pep-
tides, overlapping by 10 amino acids (10g/ml). Brieﬂy, 300,000
PBMCs per well were plated directly onto the ELISPOT plate (MAIP,
Millipore) in the presence of peptide (7 pools of 9–10 15-mer pep-
tides overlapping by 10 amino acids, each pool ﬁnal concentration
10g/ml), Ag85A (10g/ml) and PPD (20g/ml), and incubated
for 18h. SK/SD (streptokinase–streptodornase) (250units and
60units/ml) and PHA 1g/ml were used in all assays as positive
controls. Assays were performed in duplicate and the results were
averaged.
2.3. Cryopreservation of PBMC
PBMC were frozen in 1ml aliquots at a concentration of
5×106 PBMC/ml. PBMC to be frozen were centrifuged and re-
suspended in 0.5ml fetal bovine serum (FBS). A 0.5ml aliquot of
freezing mix was then added to each tube (20% dimethyl sulfoxide,
50% FBS in RPMI). Cells were immediately transferred to a Nal-
gene “Mr. Frosty” freezing container and stored overnight at−80 ◦C.
Once frozen cells were transferred for long-term storage in liquid
nitrogen.
2.4. Cell stimulation for mRNA analysis
Frozen PBMC from weeks 0, 1, 4 and 12 from six BCG, eight
MVA85A and eight BCG prime–MVA85A boost vaccinees were
thawed, washed and counted. 1×106 cells in R10 (RPMI 1640
mediumsupplementedwith 10% FBS, 2mM l-glutamine, 100 IU/ml
of penicillin and 100 IU/ml streptomycin) were plated in duplicate
in 96-well plates. One pool of 66 overlapping peptides for Ag85A
(15-mers overlapping by 10) was added to one duplicate well to a
ﬁnal concentration of 2g/ml each peptide. Antigen 85A peptide
stimulated and media only control wells were incubated for 12h at
37 ◦C 5% CO2. After incubation media was removed and cells lysed
in 350l RLT buffer (RNeasy Minikit, Qiagen). Lysed cells in RLT
buffer were stored at −20 ◦C until extraction. For IFN- blocking
assays, media was supplemented with 10g/ml anti-human IFN-
antibodies (Becton Dickinson).
2.5. Real-time reverse transcriptase (RT) PCR
TheRneasyMinikit (Qiagen)wasusedaccording to themanufac-
turers’ instructions for the extraction of total RNA from85Apeptide
stimulated and media only control PBMC from each sample. Ten
microliters of RNA extract was reverse transcribed in a total reac-
tionvolumeof20l usingoligo-dTand theOmniscriptKit (Qiagen).
cDNA was stored at −20 ◦C until use. Real-time PCR was performed
using the Roche LightCycler® and Quantitect mastermix (Qiagen).
Quantiﬁed, puriﬁed and diluted PCR product was used to gen-
erate external standard curves for each primer pair. Ct values were
converted to copy number using these curves post-ampliﬁcation.
Primerswere designed for HPRT (F: 5′-TATGGACAGGACTGAACGTC-
3′ and R: 5′-CTACAATGTGATGGCCTCCC-3′), FoxP3 (F: 5′-CACT-
TACAGGCACTCCTCCAGG-3′ and R: 5′-CCACCGTTGAGAGCTG-
GTGCAT-3′) and TGF-1 (F: 5′-GGACATCAACGGGTTCACTA-3′ and
R: 5′-CCGGTTCATGCCATGAATGG-3′). One microliter of cDNA was
used in each reaction. Cycling conditions of an initial activation
step of 15min at 95 ◦C followed by 45 cycles of 15 s at 94 ◦C, 20 s at
60 ◦C and 15 s at 72 ◦C were used for each primer pair.
2.6. TGF-ˇ1 ELISA
Serum from weeks 0, 1, 4 and 12 from 6 BCG, 8 MVA85A and
11 BCG prime–MVA85A boost vaccinees were analysed for TGF-
1 protein using the human TGF-1 ELISA kit from eBioscience
(San Diego, CA). Brieﬂy, serum was diluted 1/5 with PBS and 10l
1N HCl added to 100l of diluted sample. After 10min incubation
samples were neutralised with 10l 1N NaOH and transferred to
a pre-coated plate. Following an over night incubation at 4 ◦C the
colour was developed according to the manufacturers instructions
Plates were read at 450nm/570nm in a MultiSkan (Thermo Life
Sciences) plate reader.
2.7. Flow cytometry
FoxP3 mRNA expression was conﬁrmed using intracellular
staining for FoxP3 protein. The anti-human Foxp3 antibody
(PCH101 clone), CD4 FITC (RPA-T4), CD25 APC (BC96) were pur-
chased from eBioscience as part of the Human Regulatory T Cell
Staining Kit (San Diego, CA). Intracellular staining for FoxP3 was
performed on PBMC from subjects vaccinated with MVA85A alone
according to the manufacturers’ instructions. FACSCalibur (Becton
Dickinson)was used for ﬂowcytometry event collection and events
were analysed using FlowJo (Tree Star Inc.).
2.8. Statistical analysis
For the real-time RT-PCR data the mean Ct value of duplicate
capillaries was converted to copy number using external stan-
dard curves generated from puriﬁed and quantiﬁed PCR product.
TGF-1 and FoxP3 expression were normalised by dividing copy
number of gene by copy number of HPRT. Normalised mRNA and
serum protein values within a vaccine group were compared using
the non-parametric Wilcoxon Signed Rank test in SPSS. Corre-
lations between TGF-1 protein, IFN- ELISPOT responses and
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Table 1
Following vaccination an area under the curve analysis (AUC) was carried out between 0 and 12 weeks to measure changes in FoxP3 or TGF-1 mRNA expression
Vaccine group n Median AUC (25th, 75th percentiles)
FoxP3-unstimulated expression FoxP3 85A-stimulated expression TGF-unstimulated expression TGF 85A-stimulated expression
BCG 5 1.34 (1.26–1.63) 1.60 (1.38–1.68) 36.81 (33.53–37.61) 35.62 (34.28–38.30)
BCG–MVA 7 1.43 (0.98–2.12) 1.18 (1.02–1.84) 27.24 (21.15–36.36) 26.65 (17.73–34.39)
MVA 8 1.21 (1.07–1.42) 1.43 (1.19–1.59) 37.84 (31.06–43.30) 37.54 (31.29–44.62)
p-Valuea 0.60 0.43 0.06 0.03
The Kruskall–Wallis test (a global test for the comparison of medians) was performed to identify signiﬁcant changes in gene expression. Data are summarized using median
and interquartile range. Two subjects without data at 12 weeks had to be excluded from the analysis
a Kruskall–Wallis test.
Table 2
The expression of TGF-1 mRNA is signiﬁcantly reduced following vaccination with BCG–MVA85A when compared to BCG alone or MVA85A alone
TGF-unstimulated expression TGF 85A-stimulated expression
Diff in medians (95% CIa) p-Valueb Diff in medians (95% CIa) p-Valueb
BCG–MVA vs. BCG −8.81 (−16.07–2.58) 0.09 −10.32 (−25.53–0.79) 0.06
BCG–MVA vs. MVA −9.63 (−18.74–−0.34) 0.03 −12.47 (−25.67–−2.54) 0.02
BCG vs. MVA −1.83 (−9.86–5.92) 0.66 −2.04 (−9.93–5.73) 0.59
The Mann–Whitney test was used to determine signiﬁcant differences in gene expression.
a Estimated using the Binomial method.
b Mann–Whitney test.
CD4+CD25hiFoxP3+ cells were performed using the Spearman’s
Rank test in SPSS. Area under the curve analysis was carried out
and the three groups were compared using the Kruskall–Wallis
test. Where signiﬁcant differences were found between the three
groups, the Mann–Whitney test was used to make all pair-wise
comparisons. These analyses were carried out using STATA.
3. Results
3.1. TGF-ˇ1 but not FoxP3 mRNA expression is reduced following
vaccination with MVA85A in BCG primed subjects
The kinetics of FoxP3 mRNA and TGF-1 mRNA expression
were investigated in BCG naïve or BCG primed subjects following
vaccination with MVA85A. mRNA was measured on the day of vac-
cination and 1, 4 and 12weeks following vaccination. An area under
the curve analysis (AUC) was carried out between 0 and 12 weeks
to determine differences in expression between the vaccine groups.
A signiﬁcant difference in TGF-1 mRNA expression between the
vaccine groups was seen in PBMC stimulated with 85A peptides
(p=0.03) and a weak difference was seen in unstimulated PBMC
(p=0.06) (Table 1). There was no signiﬁcant difference in FoxP3
mRNA expression between the vaccine groups. A pair-wise test of
TGF-1 mRNA expression using Mann–Whitney showed a signiﬁ-
cant decrease in both stimulated and unstimulated TGF-1 mRNA
expression in BCG primed versus BCG naïve subjects vaccinated
with MVA85A (p=0.02, 0.03) (Table 2).
3.2. TGF-ˇ1 protein is reduced in serum following vaccination
with MVA85A in BCG primed subjects
TGF-1 mRNA was signiﬁcantly reduced in both peptide-
stimulated and -unstimulated PBMC from BCG primed subjects
vaccinated with MVA85A. TGF-1 protein is secreted as a latent
proprotein which can be activated by acidiﬁcation in vitro. Acid
activated serum TGF-1 protein levels were measured pre- and
post-vaccination to determine if the reduction in TGF-1 mRNA
reﬂected a systemic reduction in TGF-1 protein. There was a
signiﬁcant decrease in serum TGF-1 from day of vaccination
(median 4.3ng/ml) toweek 1 (median 3.7ng/ml), atweek 4 TGF-1
increased but remained signiﬁcantly below the day of vaccination
(median 4.2ng/ml) and by week 12 TGF-1 levels had decreased
again (median 3.9ng/ml) (Fig. 1). Following vaccinationwith either
BCG alone or MVA85A alone there was no signiﬁcant change in
serum TGF-1 protein (Fig. 1). Although both TGF-1 mRNA and
proteinwere reduced following vaccination of BCGprimed subjects
withMVA85A therewas no direct correlation of acid activated TGF-
1 protein and mRNA expression (p=0.294). Others have reported
a lack of direct correlation between TGF-1 mRNA and protein
([38], #130). This is most likely due to the secretion of TGF-1 as
a latent proprotein requiring proteolytic cleavage of the LAP pep-
tide (latency associated propeptide). TGF-1 is also produced by
many cell types, not just PBMC, which may account for the lack
of direct correlation between TGF-1 protein and mRNA in our
study.
Fig. 1. Serum levels of TGF-1 protein are decreased in BCG primed subjects follow-
ingboostingwithMVA85Abutnot in subjects vaccinatedwithBCGaloneorMVA85A
alone. Serum TGF-1 protein levels were measured on the day of vaccination and
1, 4 and 12 weeks post-vaccination for subjects vaccinated with BCG alone (n=6),
MVA85A alone (n=8) and in BCG primed subjects vaccinated with MVA85A (n=11).
There was a signiﬁcant decrease in serum TGF-1 protein in BCG primed subjects
following boosting with MVA85A, *p=0.0005, **p=0.021, ***p=0.021 (Wilcoxon).
Box and whisker plots showing median, 25th and 75th percentiles.
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Table 3
Higher serum TGF-1 protein on the day of vaccination results in lower IFN- ELISPOT responses to Ag85A peptides 4 months following vaccination with MVA85A alone
Week 1 Week 4 Week 8 Week 12 Week 16 Week 24 Week 52
BCG
Correlation coefﬁcient −0.06 0.23 −0.49 0.05 ND −0.03 ND
p-Value (1− tailed) 0.457 0.329 0.160 0.467 0.478
n 6 6 6 5 6
MVA85A
Correlation coefﬁcient −0.44 −0.77 −0.85 −0.71 −0.81 0.02 ND
p-Value (1− tailed) 0.136 0.020 0.004 0.024 0.007 0.484
n 8 7 8 8 8 7
BCG–MVA85A
Correlation coefﬁcient −0.07 −0.10 ND −0.16 ND −0.53 −0.57
p-Value (1− tailed) 0.416 0.385 0.315 0.059 0.090
n 11 11 11 10 7
To determine if TGF-1 protein at week 0 could effect long-term memory responses serum TGF-1 was correlated (Spearman’s correlation) with IFN- ELISPOT responses
following vaccination with BCG alone, MVA85A alone and MVA85A vaccination of BCG primed subjects.
3.3. Higher serum TGF-ˇ1 protein on the day of vaccination
results in lower IFN- ELISPOT responses to Ag85A peptide up to 4
months following vaccination with MVA85A alone
To determine if TGF-1 protein atweek 0 could effect long-term
memory responses serum TGF-1 was correlated (Spearman’s cor-
relation) with IFN- ELISPOT responses following vaccination with
BCG alone, MVA85A alone and BCG primed subjects vaccinated
with MVA85A. There was no relationship between serum TGF-1
and peptide responses to BCG at any time point. TGF-1 protein
at week 0 inversely correlated with IFN- ELISPOT responses at
weeks 4, 8, 12 and 16 following vaccinationwithMVA85A. The rela-
tionship was lost at weeks 24 following vaccination with MVA85A,
however, the peptide IFN- ELISPOT response was undetectable (0
spots) in many volunteers at this time point which may account for
the lack of correlation with TGF-1. In contrast, when MVA85A is
administered to BCG primed subjects there is little correlationwith
TGF-1 protein and IFN- ELISPOT responses at the earlier time
points. Presumably because TGF-1 is reduced in BCG primed sub-
jects vaccinated with MVA85A. However, there is a trend towards
signiﬁcance at the later time points (weeks 24 and 52) (Table 3).
3.4. Immune responses to the recall antigen SK/SD are increased
in BCG primed subjects following vaccination with MVA85A
To determine if the reduction in TGF-1 serum protein could
lead to a non-speciﬁc enhancement of effector T cell responses
in vaccinated subjects IFN- ELISPOT responses to the recall anti-
gen SK/SD were determined at weeks 0, 1, 4 and 12. SK/SD
responses were signiﬁcantly enhanced in BCG primed subjects at
week 1 (median=292SFC/million) returned to baseline at week 4
(median=107SFC/million) and were enhanced again at week 12
post-vaccination with MVA85A (median=307SFC/million) (Fig. 2).
This bi-modal increase in the SK/SD ELISPOT response seems to be
the inverse of that seen with TGF-1 protein in the serum. SK/SD
responses were unchanged following vaccination with either BCG
alone or MVA85A alone (data not shown).
3.5. SK/SD recall responses in BCG primed subjects are inversely
proportional to TGF-ˇ1 serum protein levels
Spearman’s correlation was performed to determine if the
increase in immune response to recall antigen could be related to
the decrease in TGF-1 mRNA or serum protein. The SK/SD IFN-
ELISPOT responses atweek1were signiﬁcantly inversely correlated
to TGF-1 serum protein but not TGF-1 mRNA in BCG primed
subjects (p=0.008) (Fig. 3).
Fig. 2. Immune responses to the recall antigen SK/SD are increased at both weeks
1 and 12 in BCG primed subjects vaccinated with MVA85A (n=9) (Wilcoxon). Box
and whisker plots showing median, 25th and 75th percentiles.
3.6. Inverse correlation of CD4+FoxP3+ CD25high lymphocytes
with TGF-ˇ1 serum protein and SK/SD IFN- ELISPOT responses
TGF-1 can either directly regulate effector T cells or indi-
rectly regulate effector T cells through the activity of regulatory
Fig. 3. The immune response to the recall antigen SK/SD (fold change of week 1
over week 0) is inversely proportional to TGF-1 serum protein levels (fold change
of week 1 over week 0). n=9, R=−0.769, p=0.008 (Spearman’s correlation).
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Fig. 4. The percentage of CD4+CD25hiFoxP3+ T cells 1 week post-vaccination of BCG primed subjects with MVA85A are inversely proportional to the SK/SD ELISPOT response.
The percentage of total CD4+CD25 high FoxP3 expressing cells in the lymphocyte gate was determined by (A) gating on CD4 positive CD25high cells. (B) FoxP3 expressing cells
were selected from within the CD4+CD25high gate. Representative plots from 1 of 6 subjects are shown. (C) Spearman’s correlation of the percentage of CD4+CD25hiFoxP3+
T cells with fold change in TGF-1 protein expression and SK/SD ELISPOT response.
T cells. CD4+CD25hi cells express high levels of FoxP3 and are a
highly efﬁcient regulatory subset of the CD25+ population [20].
The percentage of CD4+CD25hiFoxP3+ cells, 1 week following vac-
cination with MVA85A, in the PBMC of six BCG primed subjects
vaccinated with MVA85A were determined using ﬂow cytome-
try. To determine where the CD25hi population lay, a dot plot
showing the distribution of CD25 versus CD4 was used (Fig. 4A).
FoxP3+ lymphocytes were selected within the CD4+CD25hi gate
(Fig. 4B). The percentage of CD4+CD25hiFoxP3+ cells in PBMC
inversely correlated with SK/SD IFN- ELISPOT responses in BCG
primed subjects vaccinated with MVA85A (p=0.018, Fig. 4C). The
percentage of CD4+CD25hiFoxP3+ cells 1 week post-vaccination
positively correlated with TGF-1 protein in the serum of BCG
primed subjects (p=0.008, Fig. 4C). There was no correlation
between CD4+CD25hiFoxP3+ cells with IFN- ELISPOT responses
to 85A peptides or PPD (data not shown).
3.7. Treatment of PBMC with anti-IFN- antibodies increases the
expression of TGF-ˇ1 mRNA
A possible mechanism for the reduction in TGF-1 mRNA in
the BCG primed group is that the higher level of antigen-speciﬁc
IFN- in the BCG prime–MVA85A boost group favors the down-
regulation of TGF-1 signaling and mRNA production. Cells from
ﬁve BCG primed subjects vaccinated with MVA85A were cultured
with 85A peptides and IFN- blocking antibodies. Blocking IFN-
gamma signiﬁcantly increased TGF-1 mRNA expression in these
subjects (p=0.016) (Fig. 5).
4. Discussion
The vaccination of BCG primed subjects with MVA85A induces
levels of IFN- secreting effector T cells approximately 10 times
greater than those reported for any other recombinant MVA
[3,4,6–8,21–23]. BCG vaccination induces Ag85A-speciﬁc mem-
ory T cells and Ag85A is also present in many environmental
mycobacteria. MVA85A therefore has a potentially large pool of
Ag85A-speciﬁc memory T cells that could be expanded into IFN-
 secreting effector T cells. In this current study we have also found
that vaccination with MVA85A in BCG primed but not BCG naïve
subjects leads to a reduction in serumTGF-1 protein. Althoughwe
see no direct correlation between protein and mRNA, the reduction
in TGF-1 serum protein is likely to be controlled at the transcrip-
tional level as we see a reduction in TGF-1 mRNA in the PBMC of
vaccinated subjects. TGF-1 is a key regulator of the signaling path-
ways that initiate and maintain FoxP3 expression and is essential
for the generation and suppressive function of peripheral regula-
Fig. 5. Treatment of PBMC with anti-IFN- antibodies increases the expression of
TGF-1 mRNA. IFN- can lead to a down-regulation in TGF-1 signaling. Blocking
IFN- leads to a signiﬁcant increase in TGF-1 mRNA expression in BCG primed
subjects 4 weeks post-vaccination with MVA85A, *p=0.016 (Wilcoxon).
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tory T cells [13,17,18]. However, we saw a transient increase rather
than a decrease in the expression of FoxP3 mRNA. It is known that
FoxP3 mRNA is transiently expressed by T cells upon activation and
that this does not commit cells to a regulatory phenotype [24].
The changes in FoxP3 mRNA expression we observe in response
to MVA85A vaccination are likely to be a result of T cell activation
rather than T cell regulation.
Previously we have found that TGF-1 is associated with the
generation of regulatory T cells and higher rates of parasitic growth
in subjects infected with P. falciparum [19]. In murine studies, we
and others recently found that depletion of regulatory T cells using
a monoclonal antibody to CD25 enhances the immunogenicity of
a variety of vaccine types including BCG and MVA85A [25,26]. In
our current study the decrease in TGF-1 serum protein inversely
correlated with an increase in IFN- ELISPOT response to the recall
antigen SK/SD. The effect appears to be bi-modal with both TGF-1
and SK/SD responses returning close to baseline at week 4 before
becoming reduced/increased again at week 12. We found that both
TGF-1 serum protein and SK/SD IFN- ELISPOT responses cor-
related with the percentage of CD4+CD25hiFoxP3+ T cells in BCG
primed subjects. The increase in ELISPOT response to recall antigen
may therefore be a result of systemic reduction in TGF-1 protein
and subsequent reduction in the number of peripheral regulatory
CD4+CD25hiFoxP3+ T cells. Alternatively, T cells can bedirectly reg-
ulated through binding of active TGF-1 with the TGF-1RI and
TGF-1RII cell surface receptors. It has recently been found that
serum TGF-1 is the most prominent factor actively keeping CD4+
T cells in a resting state [27]. Classens et al. found that the removal
of even low physiological concentrations of TGF-1 had a func-
tional effect on CD4+ T cells, leading to enhanced proliferation in
response to low level TCRsignaling. Interestingly, despite thecapac-
ity of viral vectors to boost a CD8 response, the antigen-speciﬁc
response following vaccination with MVA85A has been exclusively
a CD4+ response (when measured by IFN- ELISPOT) [11,12]. This
may be due to enhanced activation and proliferation of CD4+ T
cells in response to lowered TGF-1 serum concentrations. High
TGF-1 serum protein appears to correlate with reduced effector T
cell responses to MVA85A in BCG naïve subjects. However, in BCG
primed subjects effector T cell responses are higher and there is
no association with TGF-1. Down-regulation of TGF-1 is likely,
at least in part, to account for the sustained high levels of antigen-
speciﬁc effector T cells seen after vaccination with MVA85A in BCG
primed subjects, perhaps through a reduction in the number of
circulating regulatory T cells.
Plasma TGF-1 levels are predominantly under genetic con-
trol [28]. However, IFN- can directly regulate TGF-1 through the
STAT and SMAD pathways [29]. One possible mechanism for the
reduction in TGF-1 is that the high level of antigen-speciﬁc IFN-
released following vaccination with MVA85A leads to a down-
regulation of TGF-1 mRNA via expression of SMAD 7 [29]. Indeed,
we have found that blocking IFN- leads to an increase in antigen-
speciﬁc TGF-1 mRNA expression. There is strong evidence for
TGF-1-dependent immune regulation in tuberculosis infection.
When compared tohealthy controls, TBpatients havebeen found to
have reduced IFN- production and increased TGF-1 in response
to stimulation with mycobacterial antigens [30–33]. Neutralising
TGF- leads toenhanced immune responses andclearanceof tuber-
culosis infection [30,32,34]. There is also evidence for theexpansion
of FoxP3 expressing regulatory T cells during tuberculosis infection
[35–37].
Although the number of subjects in our study is small, we have
seen that vaccination of BCG primed subjects with MVA85A results
in reduced TGF-1 mRNA in PBMC and reduced TGF-1 protein in
the serum of vaccinated subjects. This appears to limit the number
of circulating CD4+CD25hiFoxP3 positive T cells and enhance IFN-
 responses to the recall antigen SK/SD. Therefore, in BCG primed
individuals theremaybeaperiodof timeshortly followingMVA85A
vaccinationwhere greater effector T cell responses could be elicited
from a less immunogenic vaccine. This raises the possibility of
designing vaccine schedules for TB, HIV and malaria whereby the
vaccine for TB aids in the generation of protective immunity against
HIV and malaria.
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